Inflammation: Central Pathological Driver and Therapeutic Target

Katerina Lyapina^*
*Correspondence: Katerina Lyapina, Department of Structural Immunology, Sofia National Biocenter, Sofia, Bulgaria, Email:

Introduction

The inflammasome, a multiprotein complex, is crucial for innate immune responses. It details how inflammasomes sense danger signals, leading to the activation of caspases and the release of pro-inflammatory cytokines like IL-1β and IL-18. The article highlights the diverse roles of inflammasomes in infectious diseases, autoimmune conditions, and metabolic disorders, emphasizing their potential as therapeutic targets[1].

Inflammation resolution, an active process, moves beyond the traditional view of passive cessation. It details the molecular mechanisms and specialized pro-resolving mediators (SPMs) involved in clearing inflammatory debris, promoting tissue repair, and restoring homeostasis. The authors highlight novel therapeutic opportunities targeting these pathways for various chronic inflammatory diseases[2].

The NLRP3 inflammasome, a key innate immune system component, is involved in various inflammatory diseases. It discusses how the NLRP3 inflammasome senses diverse pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), leading to the production of pro-inflammatory cytokines and pyroptosis. The review elucidates its role in conditions like autoimmune diseases, metabolic disorders, and neurodegenerative diseases, proposing it as a promising therapeutic target[3].

An intricate link exists between obesity, chronic low-grade inflammation, and metabolic diseases. It elucidates how adipose tissue dysfunction in obesity leads to the infiltration of immune cells, production of pro-inflammatory cytokines, and subsequent insulin resistance and hepatic steatosis. The review also discusses potential therapeutic strategies targeting this inflammation to mitigate obesity-related metabolic complications[4].

The complex interplay between gut microbiota and the host immune system is investigated in inflammatory bowel disease (IBD). It details how dysbiosis, an imbalance in the gut microbial community, can trigger and perpetuate chronic intestinal inflammation through various mechanisms, including altered metabolite production, impaired barrier function, and aberrant immune responses. The authors explore therapeutic strategies targeting the microbiota, such as fecal microbiota transplantation and pre/probiotics[5].

Atherosclerosis is fundamentally an inflammatory disease, a concept evolving over a century. It discusses how chronic inflammation within the arterial wall drives plaque formation, progression, and rupture, leading to acute cardiovascular events. The authors highlight the importance of targeting inflammatory pathways, beyond lipid lowering, for comprehensive cardiovascular disease prevention and treatment[6].

T helper (Th) cells play a pivotal role in driving chronic inflammation characteristic of autoimmune diseases. It discusses how different Th cell subsets, such as Th1, Th2, Th17, and Treg cells, contribute to immune dysregulation and tissue damage through their specific cytokine profiles. The article highlights the complex balance between pathogenic and regulatory Th cells, and how targeting these pathways offers new therapeutic avenues for various autoimmune conditions[7].

The complex and often paradoxical role of inflammation in cancer development and progression is explored. It discusses how chronic inflammation can promote tumorigenesis by inducing genetic mutations, fostering an immunosuppressive microenvironment, and enhancing angiogenesis. Conversely, it also highlights how acute inflammatory responses can be leveraged in cancer immunotherapy. The article outlines current and emerging therapeutic strategies that modulate inflammatory pathways to improve cancer treatment outcomes[8].

The 'cytokine storm' phenomenon in severe COVID-19 cases is characterized as an uncontrolled systemic inflammatory response. It elucidates the pathogenic mechanisms involving exaggerated innate and adaptive immune activation, leading to excessive cytokine release and multiorgan damage. The review also covers diagnostic markers for identifying patients at risk and discusses various therapeutic strategies, including immunomodulators, aimed at mitigating this life-threatening hyperinflammation[9].

Underlying inflammatory mechanisms contribute to chronic pain. It elaborates on how persistent activation of immune cells, release of pro-inflammatory mediators, and sensitization of nociceptors at both peripheral and central levels drive the transition from acute to chronic pain states. The review discusses various molecular targets and pathways, including cytokines, chemokines, and glial cell activation, as potential avenues for developing more effective pain management strategies[10].

Description

The inflammasome, a multiprotein complex, is crucial for innate immune responses. It details how inflammasomes sense danger signals, leading to the activation of caspases and the release of pro-inflammatory cytokines like IL-1β and IL-18. The article highlights the diverse roles of inflammasomes in infectious diseases, autoimmune conditions, and metabolic disorders, emphasizing their potential as therapeutic targets[1]. Inflammation resolution, an active process, moves beyond the traditional view of passive cessation. It details the molecular mechanisms and specialized pro-resolving mediators (SPMs) involved in clearing inflammatory debris, promoting tissue repair, and restoring homeostasis. The authors highlight novel therapeutic opportunities targeting these pathways for various chronic inflammatory diseases[2].

The NLRP3 inflammasome, a key innate immune system component, is involved in various inflammatory diseases. It discusses how the NLRP3 inflammasome senses diverse pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), leading to the production of pro-inflammatory cytokines and pyroptosis. The review elucidates its role in conditions like autoimmune diseases, metabolic disorders, and neurodegenerative diseases, proposing it as a promising therapeutic target[3]. An intricate link exists between obesity, chronic low-grade inflammation, and metabolic diseases. It elucidates how adipose tissue dysfunction in obesity leads to the infiltration of immune cells, production of pro-inflammatory cytokines, and subsequent insulin resistance and hepatic steatosis. The review also discusses potential therapeutic strategies targeting this inflammation to mitigate obesity-related metabolic complications[4].

The complex interplay between gut microbiota and the host immune system is investigated in inflammatory bowel disease (IBD). It details how dysbiosis, an imbalance in the gut microbial community, can trigger and perpetuate chronic intestinal inflammation through various mechanisms, including altered metabolite production, impaired barrier function, and aberrant immune responses. The authors explore therapeutic strategies targeting the microbiota, such as fecal microbiota transplantation and pre/probiotics[5]. Atherosclerosis is fundamentally an inflammatory disease, a concept evolving over a century. It discusses how chronic inflammation within the arterial wall drives plaque formation, progression, and rupture, leading to acute cardiovascular events. The authors highlight the importance of targeting inflammatory pathways, beyond lipid lowering, for comprehensive cardiovascular disease prevention and treatment[6].

T helper (Th) cells play a pivotal role in driving chronic inflammation characteristic of autoimmune diseases. It discusses how different Th cell subsets, such as Th1, Th2, Th17, and Treg cells, contribute to immune dysregulation and tissue damage through their specific cytokine profiles. The article highlights the complex balance between pathogenic and regulatory Th cells, and how targeting these pathways offers new therapeutic avenues for various autoimmune conditions[7]. The complex and often paradoxical role of inflammation in cancer development and progression is explored. It discusses how chronic inflammation can promote tumorigenesis by inducing genetic mutations, fostering an immunosuppressive microenvironment, and enhancing angiogenesis. Conversely, it also highlights how acute inflammatory responses can be leveraged in cancer immunotherapy. The article outlines current and emerging therapeutic strategies that modulate inflammatory pathways to improve cancer treatment outcomes[8].

The 'cytokine storm' phenomenon in severe COVID-19 cases is characterized as an uncontrolled systemic inflammatory response. It elucidates the pathogenic mechanisms involving exaggerated innate and adaptive immune activation, leading to excessive cytokine release and multiorgan damage. The review also covers diagnostic markers for identifying patients at risk and discusses various therapeutic strategies, including immunomodulators, aimed at mitigating this life-threatening hyperinflammation[9]. Underlying inflammatory mechanisms contribute to chronic pain. It elaborates on how persistent activation of immune cells, release of pro-inflammatory mediators, and sensitization of nociceptors at both peripheral and central levels drive the transition from acute to chronic pain states. The review discusses various molecular targets and pathways, including cytokines, chemokines, and glial cell activation, as potential avenues for developing more effective pain management strategies[10].

Conclusion

This collection of reviews highlights the pervasive and critical role of inflammation in various human diseases, from fundamental immunological mechanisms to specific pathological conditions. It details the inflammasome, a key multiprotein complex in innate immunity, including the NLRP3 inflammasome, and its involvement in numerous inflammatory diseases, autoimmune conditions, and metabolic disorders, positioning it as a significant therapeutic target. The active process of inflammation resolution is also explored, emphasizing molecular mechanisms and specialized pro-resolving mediators that offer novel opportunities for drug discovery. The reviews connect chronic inflammation to specific health issues, such as obesity-associated metabolic diseases, gut microbiota dysbiosis in inflammatory bowel disease, and atherosclerosis, which is recognized as an inflammatory disease. The pivotal role of T helper cells in autoimmune inflammatory diseases is also discussed. Furthermore, the complex and often paradoxical involvement of inflammation in cancer development and progression is examined. Insights into the 'cytokine storm' phenomenon in severe COVID-19, characterized by uncontrolled systemic inflammation and hyperinflammation, are provided. Lastly, the underlying inflammatory mechanisms contributing to chronic pain are investigated. Collectively, these articles underscore inflammation as a central pathological driver and a critical area for therapeutic intervention across a wide spectrum of health challenges.

Acknowledgement

None

Conflict of Interest

None

References

Sanchita D, Ashish K, Jyoti S. "The Inflammasome: A Central Hub in Host Immunity and Disease Pathogenesis".Cells 12 (2023):1819.

Indexed at, Google Scholar, Crossref

Matthew GS, Patricia HL, Dipak P. "Resolution of inflammation: Novel opportunities for drug discovery".Nature Rev Drug Disc 20 (2021):49-65.

Indexed at, Google Scholar, Crossref

Hong-Min L, Seung-Min K, Jong-Hoon K. "NLRP3 inflammasome in inflammatory diseases".Arch Pharm Res 45 (2022):231-246.

Indexed at, Google Scholar, Crossref

Min-Seon K, Jun-Ho C, Young-Hoon K. "Obesity-associated inflammation and metabolic diseases".Exp Mol Med 55 (2023):1965-1976.

Indexed at, Google Scholar, Crossref

Jing S, Xinyi M, Qihui S. "Gut Microbiota-Host Interactions in Inflammatory Bowel Disease".Front Immunol 13 (2022):902266.

Indexed at, Google Scholar, Crossref

Peter L, Paul MR, Alan T. "Atherosclerosis is an inflammatory disease: 100 years and counting".Lancet 397 (2021):787-789.

Indexed at, Google Scholar, Crossref

Xiaochen Z, Yujie L, Chunyang W. "Role of T helper cells in autoimmune inflammatory diseases".Cell Mol Immunol 19 (2022):1024-1035.

Indexed at, Google Scholar, Crossref

Shuo L, Kai X, Mingming C. "Inflammation and cancer: New understandings and therapeutic opportunities".J Exp Clin Cancer Res 40 (2021):290.

Indexed at, Google Scholar, Crossref

Jing W, Qian Z, Juanjuan Z. "Cytokine storm in COVID-19: Pathogenesis, diagnosis, and treatment".Clin Chem Lab Med 58 (2020):1045-1054.

Indexed at, Google Scholar, Crossref

Qun L, Chun-Lei W, Yu-Bin H. "Inflammatory mechanisms in chronic pain".Front Pharmacol 13 (2022):871804.

Indexed at, Google Scholar, Crossref